Anaemia is a serious adverse effect of antiviral therapy with pegylated interferon (PEG-IFN) in combination with ribavirin (RBV) and it represents the main reason for RBV dose reduction, blood transfusion and even discontinuations of therapy ([@B7], [@B32], [@B1],[@B4], [@B9]). Haemolytic anaemia is also the most important haematologic adverse effect associated with triple therapy, with the incorporation of a new protease inhibitor into dual therapy with PEG-IFN/RBV ([@B12], [@B26]. Anaemia is presumably related to RBV use, as most patients show improved haemoglobin (Hb) levels with the reduction of RBV dose, which is reversible after the end of treatment. Age, female gender, baseline levels of Hb, creatinine clearance and platelets were also reported to be factors that influenced RBV-induced anaemia ([@B20],[@B36], [@B26].

Recent studies have shown that two single nucleotide polymorphisms (SNPs) in the inosine triphosphatase (ITPA) gene, located on chromosome 20, have been associated with protection against RBV-induced haemolytic anaemia: rs1127354 and rs7270101 ([@B7], [@B27], [@B24]). Both SNPs affect ITPA expression. Patients infected with hepatitis C virus (HCV) who carry the CC genotype at rs1127354 are more likely to develop anaemia than those who carry genotypes AC/AA, whereas at rs7270101 the reduction of Hb is greater in patients with the AA genotype than with the AC/CC genotype ([@B33]).

ITPA genotyping can help physicians make a treatment decision, especially when considering patients at high risk of developing haemolytic anaemia, such as those with advanced fibrosis and cirrhosis ([@B35], [@B26]). Determination of ITPA polymorphisms might provide important contribution for the management of patients, especially those from different ethnicities, because the majority of research about this topic has been carried out in the United States of America (USA), Europe and Asia. Moreover, there is a scarcity of studies reporting the distribution of different genotypes of ITPA for Latin American populations, as well as the significance of ITPA variants in relation to RBV-induced anaemia. In Brazil, HCV infection is a serious public health concern, being a principal cause of death from complications of HCV-related chronic liver disease, such as cirrhosis and hepatocellular carcinoma ([@B2], [@B10], [@B21]).

This study aims to evaluate ITPA polymorphism frequencies in healthy and HCV-infected patients and the association of those with the development of anaemia in a cohort of patients with chronic HCV infection on antiviral therapy living in the state of Rio de Janeiro (RJ), Brazil.

SUBJECTS, MATERIALS AND METHODS
===============================

*Patients and ethics -*This study enrolled 200 patients with chronic HCV infection (72 males, aged 54.2 ± 11.1 years) and 100 healthy individuals (34 males, aged 51.1 ± 9.7 years) living in RJ between 2013-2014. Healthy individuals and patients with chronic HCV infection on antiviral therapy were prospectively evaluated on an outpatient basis at Gaffrée & Guinle University Hospital, Clementino Fraga Filho University Hospital and Antônio Pedro University Hospital. A total of 97/200 patients who concluded antiviral therapy were investigated in relation to an association of ITPA polymorphisms with the development of anaemia. Patients were treated with PEG-IFN-α 2b, administered subcutaneously at a dose of 1.0-1.5 μg/kg weekly plus full-dose RBV (1,000-1,250 mg/day) for 24 (genotype 2 and 3) or 48 weeks (genotype 1). Haematological, biochemical and virological parameters at pretreatment (baseline) and at weeks 4, 8 and 12 were collected for comparative analysis. Drug dose reductions as a consequence of adverse effects were managed according to the severity of anaemia. Anaemia was considered as Hb levels \< 10 g/dL and/or a reduction \> 2 g/dL in comparison to baseline. A sustained virologic response (SVR) was defined as undetectable HCV-RNA in serum samples 24 weeks after the end of therapy. This study was approved by the local ethics committee and conforms to the ethical guidelines of the 1975 Declaration of Helsinki. Each patient provided written informed consent before participating in this study.

*Data collection and laboratory parameters -*Information on demographics (gender and age) and HCV genotype were obtained at study entry. Biochemical markers of liver injury \[alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (γ-GT)\], Hb, platelet count (PLT), leukocytes count (LEUC) and viral load were obtained at baseline and at weeks 4, 8 and 12. Serum aminotransferases (ALT and AST) and γ-GT were measured with an automatic analyser (Labmax Plenno; Labtest, Brazil). Haematological parameters (Hb, PLT and LEUC) were assessed with an automated cell counter (ABX PENTRA 120; ABX Diagnostics, France).

Quantification of the HCV-RNA load and determinations of HCV genotypes were performed using the Abbott Real-Time HCV assay (Abbott Laboratories, USA), which has a dynamic range of detection between 12 IU/mL (1.08 log IU/mL) and 100 million IU/mL (8.0 log IU/mL), according to the manufacturer's instructions.

*ITPA genotyping -*Blood samples were collected into ethylenediamine tetraacetic acid tubes and human genomic DNA was extracted from 200 µL whole blood using a QIAamp DNA Blood Kit (Qiagen, Germany) according to the manufacturer's directions. ITPAs variants (rs7270101 and rs1127354) were determined using direct sequencing after polymerase chain reaction (PCR) amplification. Specific primers used to target the two SNPs were: forward, 5'CGTGCTCACATGGAGAATCA3' and reverse, 5'CCTGGAAGCTACCTGGACAA3' ([@B3]). The PCR products were purified using a QIAquick gel extraction kit (Qiagen) and submitted to nucleotide sequencing reactions in both directions using a BigDye Terminator kit 3.1 (Applied Biosystems, USA) according to the manufacturer's instructions and then analysed on an ABI 3730 DNA automated sequencer (Applied Biosystems).

*Classification of predicted ITPase activity -*ITPA deficiency phenotypes were classified according to the degree of predicted ITPA deficiency based on the compound genotype of rs1127354 and rs7270101, as previously determined by biochemical analyses: 100% (AA~rs7270101~CC~rs1127354~), 60% (AC~rs7270101~CC~rs1127354~), 30% (CC~rs7270101~CC~rs1127354~), 25% (AA~rs7270101~AC~rs1127354~), 10% (AC~rs7270101~AC~rs1127354~) and \< 5% (AA~rs7270101~AA~rs1127354~) ([@B31], [@B17], [@B30], [@B25].

*Statistical analysis* - Data are expressed as frequencies and means ± standard deviation for continuous variables with a normal distribution or median and ranges for those that did not pass the normality test (Kolmogorov-Smirnov test). Bivariate analysis was performed using the Pearson's chi-square test for independence to compare categorical variables. For continuous variables with a normal distribution, homoscedasticity was tested by the Levene's test and we used the unpaired Student's *t* test to compare means (between 2 groups) or ANOVA with the Bonferroni posttest (for more than 2 groups). Continuous variables assumed not to follow a normal distribution were compared using the nonparametric Mann-Whitney *U* test (between 2 groups) or the Friedman with Dunn posttest (for more than 2 groups) statistics to compare medians. Differences between groups were considered to be statistically significant at p \< 0.05 (2-tailed). All calculations were performed using GraphPad InStat 1998, v.3.01 for Windows 95 (GraphPad Software, USA).

RESULTS
=======

*ITPA allele frequencies -*Both healthy and HCV-infected patients groups did not differ significantly in relation to gender distribution (males, 34% vs. 38%) or mean age (51.0 ± 9.7 vs*.*57.5 ± 9.4). The ITPA allele frequencies of the 300 patients included in this study are shown in [Table I](#t1){ref-type="table"}. It was possible to observe that the allelic distribution of ITPA SNPs in both groups were similar (rs7270101, p = 0.3614; rs1127354, p = 0.6589).

TABLE IInosine triphosphatase (ITPA) alleles frequency in healthy patients (n = 100) and patients infected with hepatitis C virus (HCV) (n = 200)ITPA n (%)Total (n = 300)SNPHealthy group^*a*^ (n = 100)Infected with HCV^*a*^ (n = 200)rs7270101 \[n (%)\]AA87 (87)165 (82.5)252 (84)AC11 (11)33 (16.5)44 (14.7)CC2 (2)2 (1)4 (1.3)rs1127354 \[n (%)\]CC93 (93)190 (95)283 (94.3)AC7 (7)10 (5)17 (5.7)AA0 (0)0 (0)0 (0)[^1]

In healthy individuals, AA and CC were the most prevalent genotypes at rs7270101 and rs1127354 SNPs (87% and 93%, respectively). Similarly, in patients infected with HCV, these genotypes were also the most prevalent (82.5% and 95%, respectively).

*Clinical and laboratory findings in treated patients with chronic HCV infection -*The clinical and demographic characteristics of HCV-infected patients treated with IFN/PEG-IFN plus RBV (n = 97) in this study are shown in [Table II](#t2){ref-type="table"}. Most patients were female (62%), with a mean age of 57.5 ± 9.4 years (range 28-73 years). Genotype determination in serum samples revealed that HCV genotypes 1, 1a, 1b and 3 were found in 16 (16.5%), 30 (31%), 42 (43.3%) and nine (9.2%) patients, respectively. The median serum viral load measured was 825,046.0 IU/mL (range 3,732.0-9,110,000.0 IU/mL). Overall, SVR was achieved in 32% of patients.

TABLE IIClinical and demographic characteristics of hepatitis C virus (HCV)-infected patients treated with pegylated interferon plus ribavirin (RBV) (n = 97)CharacteristicsBaseline valuesAge (years) (mean ± SD)57.5 ± 9.4Gender \[n (%)\]Male37 (38)Female60 (62)Hb (g/dL) (mean ± SD)13.98 ± 1.57Platelet count (x 10^9^/L) (mean ± SD)168.5 ± 67.5Leukocytes (x 10^9^/L) \[median (range)\]5.5 (5.6-14.1)AST^*a*^ (U/L) \[median (range)\]61.0 (15.0-276.0)ALT^*b*^ (U/L) \[median (range)\]75.0 (12.0-281.0)γ-GT^*c*^ (U/L) \[median (range)\]80.0 (14.0-290.0)HCV genotype^*d*^ \[n (%)\]116 (16.5)1a30 (31)1b42 (43.3)39 (9.2)Serum viral load^*d*^UI/mL \[median (range)\]825,046.0 (3,732.0-9,110,000.0)Log-transformed (mean ± SD)5.8 ± 0.7RBV dose reduction^*e*^ \[n (%)\]Yes17 (17.5)No31 (32)SVR^*f*^ \[n (%)\]Yes31 (32)No35 (36)[^2]

Biochemical and haematological data were analysed at baseline and after four, eight and 12 weeks of treatment. A significant and progressive reduction during antiviral treatment was observed for haematological (Hb, PLT and LEUC) and biochemical (AST, ALT and γ-GT) parameters. The mean value of pretreatment Hb was 13.98 ± 1.57 g/dL, with a significant reduction at week 4 (12.46 ± 1.56 g/dL), week 8 (11.00 ± 1.38 g/dL) and week 12 (10.65 ± 1.54 g/dL) after the start of antiviral treatment (p \< 0.0001) ([Fig. 1A](#f01){ref-type="fig"}). RBV dose reductions were required in 17.5% of patients. Mean values of PLT counts were 168.5 ± 67.5 × 10^9^/L, 139.6 ± 55.2 × 10^9^/L, 135.8 ± 65.1 × 10^9^/L and 133.9 ± 60.7 × 10^9^/L at baseline and after four, eight and 12 weeks of treatment, respectively (p \< 0.0001) ([Fig. 1B](#f01){ref-type="fig"}). Median values of LEUC were 5.5 × 10^9^/L (range 5.6-14.1 × 10^9^/L), 4.1 × 10^9^/L (range 3.6-13.0 × 10^9^/L), 3.3 × 10^9^/L (range 1.1-7.5 × 10^9^/L) and 3.0 × 10^9^/L (range 1.0-11.0 × 10^9^/L) at baseline and after four, eight and 12 weeks, respectively (p \< 0.0001) ([Fig. 1C](#f01){ref-type="fig"}).

Fig. 1:biochemical and haematological data at baseline and at four, eight and 12 weeks of treatment. A progressive decline during antiviral treatment was observed in haematological parameters. A: haemoglobin (Hb); B: platelet (PLT); C: leukocytes count (LEUC); D: values for biochemical parameters. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyl transpeptidase (γ-GT) showed a progressive decrease at baseline and throughout antiviral treatment.

In relation to biochemical parameters, median AST values were 61.0 U/L (range 15.0-276.0 U/L), 46.0 U/L (range 23.0-190.0 U/L), 38.0 U/L (range 20.0-158.0 U/L) and 36.0 U/L (range 10.0-121.0 U/L) at baseline and at week 4, 8 and 12, respectively (p \< 0.0001). Median ALT values were 75.0 U/L (range 12.0-281.0 U/L), 54.0 U/L (range 19.0-209.0 U/L), 44.5 U/L (range 9.0-240.0 U/L) and 37.0 U/L (range 9.0-150.0 U/L) at baseline and at week 4, 8 and 12, respectively (p \< 0.0001). Median γ-GT values at baseline and at week 4, 8 and 12 were as follows: 80.0 U/L (range 14.0-290.0 U/L), 96.0 U/L (range 19.3-252.0 U/L), 65.5 U/L (range 15.0-334.0 U/L) and 57.0 U/L (range 13.0-563.0 U/L), respectively (p = 0.0003) ([Fig. 1D](#f01){ref-type="fig"}).

*ITPA alleles and development of anaemia in HCV-treated patients -*In treated patients with chronic HCV infection (n = 97), the AA genotype of rs7270101 SNP was observed in 80 (83%) of patients whereas the AC/CC genotype was detected in 17 (17%) patients. At rs1127354, the CC genotype was found in 94 (97%) patients and the AC genotype occurred in three (3%) patients.

[Table III](#t3){ref-type="table"} shows the ITPA allele frequencies in relation to demographics and Hb levels at baseline and at week 4, 8 and 12 after starting antiviral treatment. Of the 80 patients with the AA genotype at rs7270101, anaemia was observed in 70 (87.5%) patients and 12 (70.6%) of the 17 patients with genotype AC/CC developed anaemia. At rs1127354, most patients who developed anaemia showed the CC genotype (86.2%). The allelic distributions of both SNPs were categorised according to gender and we observed that from the 26 males who developed anaemia, genotype AA at rs7270101 was detected in 21 (80.7%) individuals. For rs1127354, all males with anaemia presented the CC genotype.

TABLE IIIInosine triphosphatase (ITPA) alleles frequencies in relation to demographics and haemoglobin (Hb) levels during treatment in hepatitis C virus (HCV) patients (n = 97) ITPA SNPsrs7270101rs1127354AAAC/CCCCACAnemia^*a*^ \[n (%)\]    Yes70 (87.5)12 (70.6)81 (86.2)1 (33.3)No10 (12.5)5 (29.4)13 (13.8)2 (66.7)Gender^*b*^ \[n (%)\]Male with anaemia21 (80.7)5 (19.3)26 (100)0 (0)Female with anaemia49 (87.5)7 (12.5)55 (98.2)1 (1.8)Hb at baseline (mean ± SD)Male14.4 ± 2.314.9 ± 1.014.5 ± 2.114.9 ± 0.9Female13.6 ± 1.013.5 ± 0,713.6 ± 0.912.9 ± 0.0Hb at week 4 (mean ± SD)Male12.8 ± 1.413.6 ± 0.912.6 ± 1.516.0 ± 0.0Female12.0 ± 1.612.5 ± 0.912.0 ± 1.513.0 ± 0.0Hb at week 8 (mean ± SD)    Male11.4 ± 1.411.9 ± 1.011.3 ± 1.115.0 ± 0.7Female10.6 ± 1.210.8 ± 1.710.7 ± 1.29.0 ± 0.0Hb at week 12 (mean ± SD)    Male10.9 ± 1.912.0 ± 1.610.9 ± 1.814.2 ± 0.9Female10.3 ± 1.110.5 ± 1.310.3 ± 1.07.0 ± 0.0[^3]

A progressive reduction in Hb levels was observed at baseline and throughout antiviral treatment (at week 4, 8 and 12), but the Hb reduction at week 12 was relatively higher in individuals with an AA genotype (rs7270101) and/or a CC genotype (rs1127354). The distribution of ITPA genotypes according to gender revealed that men who carried the AA genotype (rs7270101) had a slightly greater reduction in Hb than women. [Fig. 2](#f02){ref-type="fig"} shows the reduction in Hb values compared with baseline at week 12 of treatment according to the ITPA genotypes. The distribution of the predicted ITPase activity according to compound genotype of rs7270101 and rs1127354, as previously determined by biochemical analyses, is shown in [Table IV](#t4){ref-type="table"}. The combination AA~rs7270101~CC~rs1127354~that yields 100% predicted ITPase activity was observed in 236/300 individuals (78.7%) of the present study cohort and the genotype combination that presented predicted ITPase activity equal to or below 30% was observed in only 21 individuals.

Fig. 2:haemoglobin (Hb) declines at variant rs7270101 single nucleotide polymorphisms (SNP) according to gender. A: comparison of Hb levels between week 12 of antiviral treatment and baseline for both genders. Sizable declines are observed; B: gender differences of Hb levels at week 12. Men who carried the AA genotype are seen to exhibit a slightly greater Hb decline than women.

TABLE IVDistribution of predicted ITPase activity according to compound genotype of rs7270101 and rs1127354 as previously determined by biochemical analyses and in our study population (n = 300)rs7270101rs1127354Predicted ITPase activity (%)^*a*^Present study population n (%)AACC100236 (78.7)ACCC6043 (14.3)CCCC304 (1.3)AAAC2516 (5.3)ACAC101 (0.3)AAAA\< 50 (0)[^4]

The relationship between ITPA genotypes and SVR demonstrated that SVR could be observed in 49% (27/55) of patients with the AA genotype and in 36% (4/11) of patients with the AC genotype (rs7270101). For rs1127354, differences between the distributions of genotypes in relation to SVR were not possible to analyse because almost all treated patients (94/97) with chronic HCV infection carried the CC genotype.

DISCUSSION
==========

Recently, genome-wide association studies identified polymorphisms in the ITPA gene in patients with chronic hepatitis C who received PEG-IFN/RBV. These studies have demonstrated a strong association with SNPs rs7270101 and rs1127354 and RBV-induced haemolytic anaemia, which have led to a better understanding of the effects of RBV-induced anaemia ([@B7], [@B27], [@B35], [@B16], [@B29],[@B34]).

The ITPA gene encodes the enzyme ITPA (ITPase) which catalyses the conversion of inosine triphosphate (ITP) to inosine monophosphate and pyrophosphate so that ITP does not accumulate in normal cells. ITP is used to maintain the red blood cell (RBC) adenosine triphosphate pool, thus preventing oxidative stress, which is thought to be a critical mediator of RBV-induced haemolysis ([@B11]). Deficiency of ITPase disrupts this cycle, resulting in an accumulation of ITP ([@B17]).

RBV (1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide) is a synthetic nucleoside analogue that has actions in vitro against a broad range of viruses ([@B22]) and has been used in combination with IFN during antiviral treatment. RBV can be incorporated into erythrocytes, where it undergoes phosphorylation to its pharmacologically active forms through adenosine kinase. The RBV triphosphate conjugates cannot cross the erythrocyte cell membrane and accumulate in the intracellular compartment, causing oxidative damage and leading to haemolysis ([@B14]. ITPase deficiency causes an accumulation of ITP in RBCs and may compete with RBV triphosphate, thereby protecting from RBV-induced haemolysis ([@B8], [@B30], [@B27], [@B13].

To the best of our knowledge, this is the first report of the frequency of ITPA gene polymorphisms in a cohort of Brazilian healthy individuals and patients infected with HCV. The overall frequency (n = 300) of allelic distribution at rs7270101 and rs1127354 shows high rates of the genotypes AA (84%) and CC (94.3%), respectively. These frequencies were different from those reported by [@B7] who showed that 48.4% of American individuals carried the AA genotype (rs7270101) and 47.6% had the CC genotype (rs1127354). By contrast, European studies demonstrate that the majority of individuals carry AA and CC genotypes for rs7270101 and rs1127354, respectively ([@B6], [@B5], [@B19], [@B23]). Among Japanese and Korean populations, the CC genotype is also more prevalent at rs1127354, but they are monoallelic for the rs7270101 AA genotype ([@B20], [@B34], [@B13]). Although the Brazilian population is known to have a strong miscegenation as a consequence of different migration flows, the allelic distribution of both SNPs in our population showed greater similarity to Caucasian populations, although the proportion of alleles associated with anaemia was slightly higher in the Brazilian population.

In this present study, anaemia was more often observed in patients presenting ITPA genotypes that were recognised as predictors of RBV-haemolytic anaemia, in accordance with studies conducted in the USA ([@B7], [@B35]), Europe ([@B5],[@B19], [@B23]) and Asia ([@B20], [@B27],[@B33], [@B13], [@B15]). Nevertheless, the frequency of the allelic distribution of both SNPs was slightly higher than that reported in the studies mentioned above, suggesting that our population is more prone to develop anaemia.

A progressive reduction in Hb, particularly at week 12 of dual therapy with PEG-IFN/RBV, was observed in this study. Anaemia, defined as Hb levels \< 10 g/dL and/or a reduction greater than 2 g/dL compared to baseline, was higher in genotypes AA (rs7270101) and CC (rs1127354) in both genders. We could observe a significant difference in the reduction in Hb up to week 12 associated with gender. For rs7270101, males who had an AA genotype showed an evident, but not statistically significant reduction (p = 0.1475) in Hb at week 12 compared to those who had the AC/CC genotype. By contrast, there was no influence of the ITPA genotype on Hb levels among female patients because the reduction was similar to that of patients who had an AA or AC/CC genotype (p = 0.5295) ([Fig. 2](#f02){ref-type="fig"}). For rs1127354, males who had a CC genotype also showed a more evident reduction in Hb when compared to those who had the AC genotype. This present study is the first to explore gender differences as possible protective cofactors from RBV-haemolytic anaemia in relation to ITPA allele distributions and Hb reductions during treatment. [@B28]detected gender differences in the incidence of RBV-haemolytic anaemia at week 4 in Austrian patients treated with PEG-IFN/RBV. According to those authors, Hb reductions were smaller in females than in males and among premenopausal females compared with postmenopausal patients. However, these differences not considered to be related to ITPA alleles at rs1127354 or rs7270101 ([@B28].

The distribution of predicted ITPase activity according to the genotype at rs7270101 and rs1127354 indicated that most (78.7%) of our population exhibited 100% of predicted ITPase activity. Only a small number of patients (7%) presented ITPase activity equal to or below 30%. ITPase activity is known to increase the probability of the development of anaemia. Additionally, most patients in our cohort exhibited the worst combination for both SNPs (AA~rs7270101~ CC~rs1127354~and AC~rs7270101~ CC~rs1127354~), which could explain why so many Brazilian patients developed RBV-induced anaemia.

Concerning ITPA polymorphisms studied in this present work and in response to antiviral treatment, no association was detected between the SVR and ITPA genotypes. Therefore, our findings are in accord with several other studies ([@B35], [@B18], [@B19], [@B13]). Moreover, almost all treated patients with chronic HCV infection were monoallelic for the rs1127354 CC genotype.

The main limitation of this present study was the relatively small sample size, although we included all patients (n = 97) who presented complete data on biochemical and haematological parameters (at baseline and weeks 4, 8 and 12) and had completed PEG-IFN/RBV antiviral therapy during the study period.

In conclusion, the allelic distribution frequency of SNPs in rs7270101 and rs1127354 showed high rates of the genotypes AA and CC, respectively, suggesting that the study population had a great propensity for developing RBV-induced anaemia. A progressive reduction in Hb during the weeks of HCV treatment based on PEG-IFN/RBV was observed in this study, however, the reduction in Hb levels at week 12 in male patients was greater than that observed among females.
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[^1]: *a*: p value was considered not significant (\< 0.05); SNP: single nucleotide polymorphism.

[^2]: *a*: aspartate aminotransferase (AST) normal values up to 37 U/L; *b*: alanine aminotransferase (ALT) normal values up to 41 U/L; *c*: gamma glutamyl transpeptidase (γ-GT) normal values between 11-50 U/L;*d*: Abbott Real-Time HCV assay (Abbott Laboratories, USA) (lower detection limit: 12 IU/mL);*e*: at least 20% of RBV dose and therapy for 20% of the scheduled treatment period (data available from 48 patients);*f*: data available from 66 patients; Hb: haemoglobin; SD: standard deviation; SVR: sustained virological response (undetectable serum HCV-RNA 24 weeks after completion of antiviral therapy).

[^3]: *a*: defined as Hb levels \< 10 g/dL and/or decline \> 2 g/dL; *b*: male = 37, female = 60; SD: standard deviation; SNP: single nucleotide polymorphisms.

[^4]: : Sumi et al. (2002), Maeda et al. (2005), Shipkova et al. (2006) and Rembeck et al. (t2014).
